BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND HIF1A, Q16665, 3091, ENSG00000100644, MOP1, HIF1-ALPHA, PASD8, HIF-1alpha AND Diagnosis
24 results:

  • 1. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Evaluations of the combined use of blood- and tissue-based protein biomarkers for pancreatic cancer.
    Wiewiora M; Jopek J; Świętochowska E; Grynkiewicz M; Piecuch J
    Clin Hemorheol Microcirc; 2024; 86(3):383-393. PubMed ID: 37955083
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Blood-based protein biomarkers and red blood cell aggregation in pancreatic cancer.
    Wiewiora M; Jopek J; Świętochowska E; Sławomir G; Piecuch J; Gąska M; Piecuch J
    Clin Hemorheol Microcirc; 2023; 85(4):371-383. PubMed ID: 37718785
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS.
    Chao A; Huang HJ; Lin CY; Lee CH; Lin CH; Chao AS; Lai CH; Chang TC; Wu KY; Wu RC
    Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37655726
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The association of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α protein expression with clinicopathological characteristics in papillary thyroid carcinoma: A meta-analysis.
    Lin X; Su H; Huo J; Zhang F
    Medicine (Baltimore); 2023 Jun; 102(24):e34045. PubMed ID: 37327294
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1.
    Lin J; Wang X; Zhai S; Shi M; Peng C; Deng X; Fu D; Wang J; Shen B
    J Hematol Oncol; 2022 Sep; 15(1):128. PubMed ID: 36068586
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Development and Validation of a Hypoxia-related Prognostic Model for Ovarian cancer.
    Xie L; Pan M; Zhang Z; Jiang X; Chen Y; Liu G; Chen Y; Zeng Y; Guan J; Lu R; Zeng L
    Recent Pat Anticancer Drug Discov; 2022; 18(2):161-173. PubMed ID: 35747984
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Studying the Anti-Tumor Effects of siRNA Gene Silencing of Some Metabolic Genes in Pancreatic Ductal Adenocarcinoma.
    Al Hanjori AS; Alshaer W; Al-Anati B; Wehaibi S; Zihlif M
    Curr Mol Pharmacol; 2021 Oct; 14(4):604-619. PubMed ID: 33045974
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
    Su S; Dou H; Wang Z; Zhang Q
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):224-233. PubMed ID: 32905663
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hypoxia-Induced TGFBI as a Serum Biomarker for Laboratory diagnosis and Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.
    Yang L; Cui R; Li Y; Liang K; Ni M; Gu Y
    Lab Med; 2020 Jul; 51(4):352-361. PubMed ID: 31626700
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells.
    Chen C; Sun J; Chen S; Liu Y; Zhu S; Wang Z; Chang S
    Int J Nanomedicine; 2019; 14():753-769. PubMed ID: 30718954
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Association of the hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms with prognosis in ovarian clear cell carcinoma.
    Suzuki H; Yano M; Miyazawa M; Miyazawa M; Ogane N; Hasegawa K; Tsuda H; Yoshida M; Okagaki R; Ishihara O; Yasuda M
    J Ovarian Res; 2019 Jan; 12(1):7. PubMed ID: 30678691
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic cancer Metastasis.
    Wang X; Luo G; Zhang K; Cao J; Huang C; Jiang T; Liu B; Su L; Qiu Z
    Cancer Res; 2018 Aug; 78(16):4586-4598. PubMed ID: 29880482
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Investigation of hypoxia networks in ovarian cancer via bioinformatics analysis.
    Zhang K; Kong X; Feng G; Xiang W; Chen L; Yang F; Cao C; Ding Y; Chen H; Chu M; Wang P; Zhang B
    J Ovarian Res; 2018 Feb; 11(1):16. PubMed ID: 29482638
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer.
    Shen W; Li HL; Liu L; Cheng JX
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2596-2603. PubMed ID: 28678326
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.
    Pang Y; Yang C; Schovanek J; Wang H; Bullova P; Caisova V; Gupta G; Wolf KI; Semenza GL; Zhuang Z; Pacak K
    Oncotarget; 2017 Apr; 8(14):22313-22324. PubMed ID: 28423608
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Hypoxia is important in F‑18 FDG accumulation in thecoma‑fibroma tumors on F‑18 FDG PET/CT scans.
    Seino H; Ono S; Miura H; Morohashi S; Wu Y; Tsushima F; Takai Y; Kijima H
    Mol Med Rep; 2016 May; 13(5):3821-7. PubMed ID: 27035330
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid cancer diagnosis and Extent.
    Angell TE; Lechner MG; Smith AM; Martin SE; Groshen SG; Maceri DR; Singer PA; Epstein AL
    Thyroid; 2016 Mar; 26(3):381-9. PubMed ID: 26756227
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia.
    Zhu P; Ning Y; Yao L; Chen M; Xu C
    J Exp Clin Cancer Res; 2010 Sep; 29(1):124. PubMed ID: 20831794
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.